HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 12, December 2017 – Skin diseases and allergic reactions       » Gigantic DNA database to be built in Nanjing       » Ineffective baby vaccines by two companies recalled       » Head transplant 'never' to be allowed       » Asia-Pacific, the rising region for cancer vaccine clinical trials       » The hard truth about Eczema      
EYE ON CHINA
Key Diabetes Receptor Structure Determined by International Collaboration
Shanghai Led Consortium Produces High Resolution 3D map of GLP-1R

SHANGHAI — An international team led by the iHuman Institute, ShanghaiTech University determined the molecular structure of the human glucagon-like peptide-1 receptor (GLP-1R). The results, described in the paper entitled "Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators", appears May 17, 2017 in the journal Nature. This study is published together in Nature with a companion paper led by colleagues at the Shanghai Institute of Materia Medica (SIMM) describing the full length glucagon receptor.

GLP-1R is a well-recognized drug target for type 2 diabetes, exemplified by several peptidic therapeutic agents on the market, with combined sales of several billions of dollars each year. Worldwide, the costs associated with treating diabetes and its complications are estimated to exceed $200bn a year. Diabetes is growing at an alarming rate throughout the world, with the most significant and recent growth occurring in China.

The GLP-1R structure was determined in complex with negative allosteric modulators (NAMs). The NAMs block the activation of GLP-1R by inserting into the cavity between helices VI and VII, while PAMs bind mainly to the space between helices V and VI enabling the activation. "This structure is one of the holy grails of GPCR drug discovery," said Professor Raymond Stevens at the iHuman Institute, ShanghaiTech University who co-led the study.

Orally available small molecule therapeutics have been vigorously sought after by many pharmaceutical companies for several decades to replace the peptides. "GPCRs that bind peptides can be particularly challenging for small molecule drug discovery given multiple points of connection," said iHuman Associate Professor Gaojie Song.

"This major undertaking started in 2002 when we were looking for small molecule GLP-1R agonists," said Professor Ming-Wei Wang of SIMM and Fudan University who co-led the study. "Our failed efforts in making the first orally active GLP-1R agonist Boc5 led us to conclude that high resolution structural biology is the preferred solution to drugability."

Collaborating institutions include Vrije Universiteit Amsterdam, University of Southern California, and Novo Nordisk. Financial support for this work comes from the Shanghai Municipal Government, ShanghaiTech University, National "1000 Talents Program for Foreign Experts", Shanghai "Pujiang Talents", GPCR Consortium, Chinese Academy of Sciences.

Related Links:

- http://ihuman.shanghaitech.edu.cn/

- http://english.simm.cas.cn/

Source: ShanghaiTech University

Click here for the complete issue.

NEWS CRUNCH  
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
news MIT Technology Review announces 2018's 10 'Innovators Under 35 Asia'
news Novogen becomes Kazia Therapeutics
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Paediatric Illnesses
December:
Skin Diseases and Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy